A Phase 3 interventional study of liraglutide and placebo in Metabolism and Nutrition Disorder and Obesity, sponsored by Novo Nordisk A/S. Completed at 32 sites in 8 countries. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-07-06.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.
Among the 79 studies testing liraglutide in Obesity, this one is the 44th largest by enrollment, is one of 4 that started in 2015, is one of 17 in phase 3, and was the 19th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Peking University Third Hospital · Sites in China
Ages 20–40 · Women only
Brigham and Women's Hospital · Sites in South Africa
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18–70
Emirates Health Services (EHS) · Sites in United Arab Emirates
Ages 22–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 6 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 18 · Phase 4 37
First in 2007; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is below the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 70 across the 79 interventional studies. Of the 54 that completed or were terminated, 24 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 79 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 129th largest by enrollment of the 166 interventional ones that give a count, is one of 4 that started in 2015, is one of 62 in phase 3, and was the 16th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
2 of the studies testing liraglutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
| NCT02944500Beth Israel Deaconess Medical CenterSaxenda: Underlying Mechanisms and Clinical Outcomes | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 79 studies testing liraglutide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's enrollment of 56 is below the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutrition Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: liraglutide
Drug: placebo
Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks
Change in BMI SDS from baseline to week 16 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=\[(y / M)\^L - 1\] / S\*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.
Time frame: Week 0, Week 16
Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks
Change in BMI SDS from baseline to week 52 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=\[(y / M)\^L - 1\] / S\*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.
Time frame: Week 0, Week 52
Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 16
Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 16.
Time frame: At week 16
Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 52
Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 52.
Time frame: At week 52
Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 16
Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 16.
Time frame: At week 16
Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 52
Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 52.
Time frame: At week 52
Percentage of Participants With no Increase in BMI SDS at Week 16
Percentage of participants with no increase in BMI SDS at week 16 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 16 and 'No' infers percentage of participants with increase in BMI SDS at week 16.
Time frame: At week 16
Percentage of Participants With no Increase in BMI SDS at Week 52
Percentage of participants with no increase in BMI SDS at week 52 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 52 and 'No' infers percentage of participants with increase in BMI SDS at week 52.
Time frame: At week 52
Change in BMI From Baseline at Week 16
Change in body mass index (BMI) from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in BMI From Baseline at Week 52
Change in body mass index (BMI) from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Body Weight (Kilogram (kg)) From Baseline at Week 16
Change in body weight (kg) from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Body Weight (kg) From Baseline at Week 52
Change in body weight (kg) from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Body Weight (Pounds (lb)) From Baseline at Week 16
Change in body weight (lb) from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Body Weight (lb) From Baseline at Week 52
Change in body weight (lb) from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Body Weight (Percentage [%]) From Baseline at Week 16
Change in body weight (%) from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Body Weight (%) From Baseline at Week 52
Change in body weight (%) from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Waist Circumference From Baseline at Week 16
Change in waist circumference from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Waist Circumference From Baseline at Week 52
Change in waist circumference from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Waist-to-hip Circumference Ratio From Baseline at Week 16
Change in waist-to-hip circumference ratio from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Waist-to-hip Circumference Ratio From Baseline at Week 52
Change in waist-to-hip circumference ratio from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 16
Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 16 is presented. The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.
Time frame: Week 0, week 16
Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 52
Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 52 is presented.The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.
Time frame: Week 0, week 52
Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 16
Change in hsCRP from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 52
Change in hsCRP from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Total Cholesterol From Baseline at Week 16
Change in Total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 16 is presented as ratio to baseline.
Time frame: Week 0, week 16
Change in Total Cholesterol From Baseline at Week 52
Change in total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 52 is presented as ratio to baseline.
Time frame: Week 0, week 52
Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 16
Change in LDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.
Time frame: Week 0, week 16
Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 52
Change in LDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.
Time frame: Week 0, week 52
Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 16
Change in HDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.
Time frame: Week 0, week 16
Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 52
Change in HDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.
Time frame: Week 0, week 52
Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 16
Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.
Time frame: Week 0, week 16
Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 52
Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.
Time frame: Week 0, week 52
Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 16
Change in VLDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.
Time frame: Week 0, week 16
Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 52
Change in VLDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.
Time frame: Week 0, week 52
Change in Triglycerides From Baseline at Week 16
Change in triglycerides (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.
Time frame: Week 0, week 16
Change in Triglycerides From Baseline at Week 52
Change in triglycerides (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.
Time frame: Week 0, week 52
Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 16
Change in free fatty acids (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.
Time frame: Week 0, week 16
Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 52
Change in free fatty acids (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.
Time frame: Week 0, week 52
Change in Systolic and Diastolic Blood Pressure From Baseline at Week 16
Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Systolic and Diastolic Blood Pressure From Baseline at Week 52
Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Glycosylated Haemoglobin (HbA1c) From Baseline at Week 16
Change in HbA1c from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in HbA1c From Baseline at Week 52
Change in HbA1c from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Fasting Plasma Glucose (FPG) From Baseline at Week 16
Change in FPG from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in FPG From Baseline at Week 52
Change in FPG from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Fasting Insulin From Baseline at Week 16
Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 16 is presented as ratio to baseline.
Time frame: Week 0, week 16
Change in Fasting Insulin From Baseline at Week 52
Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 52 is presented as ratio to baseline.
Time frame: Week 0, week 52
Change in Fasting C Peptide From Baseline at Week 16
Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 16 is presented as ratio to baseline.
Time frame: Week 0, week 16
Change in Fasting C Peptide From Baseline at Week 52
Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 52 is presented as ratio to baseline.
Time frame: Week 0, week 52
Number of Participants in Glycaemic Category at Week 16
Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 16 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \<5.6 mmol/L (\<100 mg/dL) and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.
Time frame: week 16
Number of Participants in Glycaemic Category at Week 52
Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 52 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \<5.6 mmol/L (\<100 mg/dL) and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.
Time frame: Week 52
Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 16
Change in HOMA-B from baseline to week 16 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5).
Time frame: Week 0, week 16
Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 52
Change in HOMA-B from baseline to week 52 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5).
Time frame: Week 0, week 52
Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 16
Change in HOMA-IR from baseline to week 16 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose \[mmol/L\] x fasting insulin \[mmol/L\]/ 22.5.
Time frame: Week 0, week 16
Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 52
Change in HOMA-IR from baseline to week 52 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose \[mmol/L\] x fasting insulin \[mmol/L\]/ 22.5.
Time frame: Week 0, week 52
Number of Treatment Emergent Adverse Events
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or using a medicinal product, whether or not considered related to the medicinal product or usage. All AEs reported here are TEAEs. TEAE is defined as an event that had onset date during the on-treatment period. The endpoint was evaluated based on the data from on-treatment period. On-treatment period included AEs are with an onset date on or after the first day of trial product administration and any of the following dates, whichever came first: a) 14 days after the last day on trial product, or b) Follow-up visit (week 54) for participants with trial product discontinuation, or c) Last study visit (participants withdrawn without follow-up visit (week 54)).
Time frame: From week 0 to week 54
Number of Severe Treatment Emergent Episodes of Hypoglycaemia
Hypoglycaemic episode (blood glucose less than or equal to (\<=) 3.9 mmol/L (70 mg/dL) Or greater than (\>) 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms) is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Severe hypoglycaemia defined by American Diabetes Association (ADA) 2013 and International Society for Paediatric and Adolescent Diabetes (ISPAD) 2018: hypoglycaemic episode associated with severe cognitive impairment requiring external assistance for recovery. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).
Time frame: From week 0 to week 54
Number of Blood Glucose Confirmed Symptomatic Episodes of Hypoglycaemia
Symptomatic blood glucose confirmed hypoglycaemia: An episode that is blood glucose confirmed by plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episode is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).
Time frame: From week 0 to week 54
Number of Participants With Occurrence of Anti-liraglutide Antibodies
Number of participants with occurrence of anti-liraglutide antibodies is presented. In the below table, 'Yes' infers number of participants with occurrence of anti- liraglutide antibodies and 'No' infers number of participants without anti- liraglutide antibodies.
Time frame: From week 0 to week 54
Number of Participants With Change in Electrocardiogram (ECG) From Baseline at Week 16
A 12-lead ECG was performed at baseline (week 0) and week 16 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and weeks 16 are presented.
Time frame: Week 0, Week 16
Number of Participants With Change in ECG From Baseline at Week 52
A 12-lead ECG was performed at baseline (week 0) and week 52 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and week 52 are presented.
Time frame: Week 0, Week 52
Change in Pulse From Baseline at Week 16
Change in pulse from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Pulse From Baseline at Week 52
Change in pulse from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Haematology: Haemoglobin From Baseline at Week 16
Change in haemoglobin from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Haematology: Haemoglobin From Baseline at Week 52
Change in haemoglobin from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Haematology: Haematocrit From Baseline at Week 16
Change in haematocrit from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Haematology: Haematocrit From Baseline at Week 52
Change in haematocrit from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 16
Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 52
Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Haematology: Erythrocytes From Baseline at Week 16
Change in erythrocytes from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Haematology: Erythrocytes From Baseline at Week 52
Change in erythrocytes from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 16
Change in creatinine and bilirubin (total) from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 52
Change in creatinine and bilirubin (total) from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 16
Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 52
Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 16
Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 52
Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Biochemistry: Albumin From Baseline at Week 16
Change in albumin from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Biochemistry: Albumin From Baseline at Week 52
Change in albumin from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 16
Change in CEA serum from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 52
Change in CEA serum from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Hormone Level: Calcitonin From Baseline at Week 16
Change in calcitonin from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Hormone Level: Calcitonin From Baseline at Week 52
Change in calcitonin from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 16
Change in TSH and prolactin from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 52
Change in TSH and prolactin from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 16
Change in free T4 and ACTH from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 52
Change in free T4 and ACTH from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 16
Change in IGF-1 and cortisol from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 52
Change in IGF-1 and cortisol from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 16
Change in DHEAS from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 52
Change in DHEAS from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 16
Change in LH and FSH from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 52
Change in LH and FSH from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Hormone Level: Estradiol (Females) From Baseline at Week 16
Change in estradiol (only for females) from baseline to week 16 is presented.
Time frame: Week 0, week 16
Change in Hormone Level: Estradiol (Females) From Baseline at Week 52
Change in estradiol (only for females) from baseline to week 52 is presented.
Time frame: Week 0, week 52
Change in Hormone Level: Testosterone (Males) From Baseline at Week 16
Change in testosterone (only for males) from baseline to week 16 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.
Time frame: Week 0, week 16
Change in Hormone Level: Testosterone (Males) From Baseline at Week 52
Change in testosterone (only for males) from baseline to week 52 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.
Time frame: Week 0, week 52
Number of Participants With Change in Pubertal Status From Baseline at Week 16
This outcome measure presents "pubertal status results" which is based on Tanner staging recorded at baseline (week 0), week 16. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult".
Time frame: Week 0, week 16
Number of Participants With Change in Pubertal Status From Baseline at Week 52
This outcome measure presents "pubertal status results" which is based on Tanner staging recorded at baseline (week 0) and week 52. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult".
Time frame: Week 0, week 52
Number of Participants With Change in Physical Examination From Baseline at Week 16
This outcome measure presents number of participants with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0), week 16. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.
Time frame: Week 0, week 16
Number of Participants With Change in Physical Examination From Baseline at Week 52
This outcome measure presents number of participants with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0) and week 52. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.
Time frame: Week 0, week 52
Height Velocity at Week 16
Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Weeks 16 is presented.
Time frame: Week 16
Height Velocity at Week 52
Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Week 52 are presented.
Time frame: week 52
Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 16
C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \[C-CASA\]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is "yes" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is "yes" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with "suicidal ideation or suicidal behaviour on C-SSRS" assessed at baseline (week 0), week 16. The questionnaire was not used in Part B due to the young age of the participants in Part B.
Time frame: Week 0, week 16
Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 52
C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \[C-CASA\]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is "yes" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is "yes" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with "suicidal ideation or suicidal behaviour on C-SSRS" assessed at baseline (week 0), week 52. The questionnaire was not used in Part B due to the young age of the participants in Part B.
Time frame: Week 0, week 52
Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 16
Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 16. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.
Time frame: Week 0, week 16
Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 52
Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 52. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.
Time frame: Week 0, week 52
The trial was conducted at 20 sites in 8 countries as follows: Australia (2), Canada (1), France (7), Italy (2), Netherlands (1), New Zealand (1), Turkey (3), and the United States (3).
| Milestone | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo |
|---|---|---|---|---|
| Started | 20 | 12 | 17 | 7 |
| Safety analysis set (sas) | 20 | 12 | 17 | 7 |
| Full analysis set (fas) | 19 | 12 | 17 | 7 |
| Completed | 17 | 9 | 15 | 7 |
| Not completed | 3 | 3 | 2 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 1 | 0 |
| Withdrew: Unclassified | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
Change in BMI SDS from baseline to week 16 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=\[(y / M)\^L - 1\] / S\*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.
| SDS score | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks | -0.18 ± 0.21 | -0.18 ± 0.23 | -0.50 ± 0.65 | -0.48 ± 0.39 | -0.33 ± 0.49 | -0.29 ± 0.32 |
Change in BMI SDS from baseline to week 52 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=\[(y / M)\^L - 1\] / S\*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.
| SDS score | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks | -0.27 ± 0.37 | -0.13 ± 0.25 | -0.79 ± 1.21 | -0.71 ± 0.68 | -0.50 ± 0.88 | -0.36 ± 0.53 |
Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 16.
| Percentage of participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Yes | 27.8 | 8.3 | 37.5 | 57.1 | 32.4 | 26.3 |
| No | 72.2 | 91.7 | 62.5 | 42.9 | 67.6 | 73.7 |
Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 52.
| Percentage of participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Yes | 29.4 | 18.2 | 35.7 | 42.9 | 32.3 | 27.8 |
| No | 70.6 | 81.8 | 64.3 | 57.1 | 67.7 | 72.2 |
Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 16.
| Percentage of participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Yes | 0 | 0 | 6.3 | 14.3 | 2.9 | 5.3 |
| No | 100 | 100 | 93.8 | 85.7 | 97.1 | 94.7 |
Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 52.
| Percentage of participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Yes | 11.8 | 0 | 14.3 | 28.6 | 12.9 | 11.1 |
| No | 88.2 | 100 | 85.7 | 71.4 | 87.1 | 88.9 |
Percentage of participants with no increase in BMI SDS at week 16 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 16 and 'No' infers percentage of participants with increase in BMI SDS at week 16.
| Percentage of participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Yes | 66.7 | 75.0 | 87.5 | 100 | 76.5 | 84.2 |
| No | 33.3 | 25.0 | 12.5 | 0 | 23.5 | 15.8 |
Percentage of participants with no increase in BMI SDS at week 52 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 52 and 'No' infers percentage of participants with increase in BMI SDS at week 52.
| Percentage of participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Yes | 70.6 | 72.7 | 78.6 | 100 | 73.3 | 81.3 |
| No | 29.4 | 27.3 | 21.4 | 0 | 26.7 | 18.8 |
Change in body mass index (BMI) from baseline to week 16 is presented.
| kilogram per meter square (kg/m^2) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in BMI From Baseline at Week 16 | -0.9 ± 1.4 | -0.8 ± 1.6 | -1.1 ± 1.5 | -1.5 ± 1.7 | -1.0 ± 1.4 | -1.1 ± 1.6 |
Change in body mass index (BMI) from baseline to week 52 is presented.
| kg/m^2 | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in BMI From Baseline at Week 52 | 0.8 ± 2.2 | -0.1 ± 2.1 | -0.6 ± 3.3 | -0.7 ± 2.7 | -0.7 ± 2.7 | -0.4 ± 2.3 |
Change in body weight (kg) from baseline to week 16 is presented.
| (kilogram (kg)) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Body Weight (Kilogram (kg)) From Baseline at Week 16 | -1.7 ± 3.6 | -1.1 ± 5.0 | -0.6 ± 2.2 | -1.0 ± 2.7 | -1.2 ± 3.0 | -1.0 ± 4.2 |
Change in body weight (kg) from baseline to week 52 is presented.
| kilogram | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Body Weight (kg) From Baseline at Week 52 | -0.4 ± 6.3 | 1.9 ± 6.0 | 3.0 ± 6.6 | 2.8 ± 5.2 | 1.1 ± 6.5 | 2.3 ± 5.6 |
Change in body weight (lb) from baseline to week 16 is presented.
| pounds (lb) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Body Weight (Pounds (lb)) From Baseline at Week 16 | -3.7 ± 7.8 | -2.4 ± 11.0 | -1.4 ± 4.8 | -2.1 ± 5.9 | -2.6 ± 6.6 | -2.3 ± 9.2 |
Change in body weight (lb) from baseline to week 52 is presented.
| pounds | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Body Weight (lb) From Baseline at Week 52 | -0.9 ± 13.9 | 4.3 ± 13.2 | 6.7 ± 14.4 | 6.2 ± 11.5 | 2.5 ± 14.4 | 5.0 ± 12.3 |
Change in body weight (%) from baseline to week 16 is presented.
| Percent change in body weight | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Body Weight (Percentage [%]) From Baseline at Week 16 | -1.7 ± 3.8 | -0.7 ± 3.7 | -1.1 ± 4.1 | -2.2 ± 5.5 | -1.4 ± 3.9 | -1.2 ± 4.3 |
Change in body weight (%) from baseline to week 52 is presented.
| Percent change in body weight | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Body Weight (%) From Baseline at Week 52 | -0.4 ± 6.5 | 2.3 ± 5.7 | 6.3 ± 12.1 | 4.9 ± 8.6 | 2.6 ± 9.9 | 3.3 ± 6.9 |
Change in waist circumference from baseline to week 16 is presented.
| centimeters (cm) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Waist Circumference From Baseline at Week 16 | -2.50 ± 4.52 | -2.44 ± 7.84 | -0.73 ± 6.14 | -1.04 ± 4.53 | -1.70 ± 5.31 | -1.92 ± 6.70 |
Change in waist circumference from baseline to week 52 is presented.
| centimeter | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Waist Circumference From Baseline at Week 52 | -2.98 ± 8.68 | -3.48 ± 7.32 | 0.45 ± 8.05 | 0.97 ± 5.99 | -1.49 ± 8.45 | -2.09 ± 7.06 |
Change in waist-to-hip circumference ratio from baseline to week 16 is presented.
| Waist-to-hip circumference ratio | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Waist-to-hip Circumference Ratio From Baseline at Week 16 | -0.01 ± 0.04 | -0.02 ± 0.06 | 0.00 ± 0.06 | 0.01 ± 0.04 | -0.01 ± 0.05 | -0.01 ± 0.05 |
Change in waist-to-hip circumference ratio from baseline to week 52 is presented.
| waist-to-hip circumference ratio | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Waist-to-hip Circumference Ratio From Baseline at Week 52 | -0.01 ± 0.06 | -0.04 ± 0.06 | -0.02 ± 0.05 | -0.01 ± 0.07 | -0.02 ± 0.06 | -0.03 ± 0.06 |
Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 16 is presented. The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.
| Score on a scale | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Hyperphagia behaviour score | -0.8 ± 2.01 | -1.7 ± 4.14 | -1.2 ± 3.83 | -2.6 ± 2.07 | -1.0 ± 2.97 | -2.0 ± 3.48 |
| Hyperphagia drive score | -0.9 ± 2.80 | -0.9 ± 2.61 | -1.8 ± 2.97 | -2.0 ± 2.89 | -1.3 ± 2.87 | -1.3 ± 2.69 |
| Hyperphagia severity score | -0.6 ± 1.54 | -0.3 ± 2.46 | -0.1 ± 1.65 | 0.1 ± 1.46 | -0.4 ± 1.59 | -0.2 ± 2.12 |
| Hyperphagia total score | -2.4 ± 5.55 | -2.9 ± 5.79 | -3.1 ± 7.28 | -4.4 ± 5.65 | -2.7 ± 6.34 | -3.5 ± 5.63 |
Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 52 is presented.The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.
| Score on a scale | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Hyperphagia behaviour score | -0.9 ± 3.20 | -0.6 ± 2.62 | -0.7 ± 4.63 | -2.6 ± 3.65 | -0.8 ± 3.82 | -1.3 ± 3.00 |
| Hyperphagia drive score | -2.2 ± 2.90 | -0.5 ± 2.42 | -1.1 ± 3.99 | -1.4 ± 4.45 | -1.7 ± 3.41 | -0.8 ± 3.06 |
| Hyperphagia severity score | -1.3 ± 1.81 | -0.9 ± 2.51 | -0.4 ± 2.73 | -1.4 ± 1.82 | -0.9 ± 2.27 | -1.1 ± 2.26 |
| Hyperphagia total score | -4.4 ± 6.57 | -2.1 ± 6.11 | -2.1 ± 10.11 | -5.4 ± 8.32 | -3.4 ± 8.23 | -3.1 ± 6.77 |
Change in hsCRP from baseline to week 16 is presented.
| Milligram per liter (mg/L) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 16 | 0.79 ± 2.58 | -0.57 ± 6.61 | -2.79 ± 8.03 | 1.87 ± 2.12 | -0.61 ± 5.57 | 0.24 ± 5.57 |
Change in hsCRP from baseline to week 52 is presented.
| mg/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 52 | 0.25 ± 2.55 | 0.14 ± 3.67 | -2.42 ± 9.19 | -0.37 ± 0.84 | -0.89 ± 6.31 | -0.03 ± 2.99 |
Change in Total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 16 is presented as ratio to baseline.
| Ratio of total cholesterol | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Total Cholesterol From Baseline at Week 16 | 0.99 ± 0.10 | 1.06 ± 0.14 | 1.02 ± 0.11 | 0.97 ± 0.10 | 1.00 ± 0.10 | 1.03 ± 0.14 |
Change in total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 52 is presented as ratio to baseline.
| Ratio of total cholesterol | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Total Cholesterol From Baseline at Week 52 | 1.00 ± 0.18 | 1.06 ± 0.15 | 1.01 ± 0.12 | 1.07 ± 0.07 | 1.01 ± 0.15 | 1.06 ± 0.13 |
Change in LDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.
| Ratio of LDL-cholesterol | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 16 | 1.01 ± 0.15 | 1.13 ± 0.19 | 1.04 ± 0.17 | 0.96 ± 0.14 | 1.02 ± 0.16 | 1.07 ± 0.19 |
Change in LDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.
| Ratio of LDL-cholesterol | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 52 | 1.02 ± 0.22 | 1.12 ± 0.23 | 0.99 ± 0.19 | 1.06 ± 0.10 | 1.01 ± 0.20 | 1.10 ± 0.19 |
Change in HDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.
| Ratio of HDL-cholesterol | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 16 | 0.96 ± 0.14 | 1.00 ± 0.20 | 1.01 ± 0.14 | 1.12 ± 0.13 | 0.98 ± 0.14 | 1.04 ± 0.19 |
Change in HDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.
| Ratio of HDL-cholesterol | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 52 | 0.99 ± 0.19 | 1.02 ± 0.17 | 1.06 ± 0.16 | 1.08 ± 0.12 | 1.02 ± 0.18 | 1.04 ± 0.15 |
Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.
| Ratio of non-HDL cholesterol | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 16 | 1.02 ± 0.16 | 1.09 ± 0.15 | 1.03 ± 0.16 | 0.93 ± 0.12 | 1.02 ± 0.15 | 1.04 ± 0.16 |
Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.
| Ratio of non-HDL cholesterol | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 52 | 1.02 ± 0.22 | 1.07 ± 0.19 | 1.00 ± 0.16 | 1.07 ± 0.13 | 1.01 ± 0.19 | 1.07 ± 0.17 |
Change in VLDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.
| Ratio of VLDL cholesterol | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 16 | 1.05 ± 0.36 | 0.98 ± 0.27 | 1.05 ± 0.46 | 0.80 ± 0.17 | 1.05 ± 0.40 | 0.93 ± 0.25 |
Change in VLDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.
| Ratio of VLDL cholesterol | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 52 | 1.06 ± 0.35 | 0.95 ± 0.36 | 1.03 ± 0.26 | 1.13 ± 0.31 | 1.04 ± 0.31 | 1.01 ± 0.34 |
Change in triglycerides (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.
| Ratio of triglycerides | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Triglycerides From Baseline at Week 16 | 1.04 ± 0.36 | 0.99 ± 0.26 | 1.05 ± 0.44 | 0.80 ± 0.18 | 1.05 ± 0.39 | 0.93 ± 0.25 |
Change in triglycerides (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.
| Ratio of triglycerides | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Triglycerides From Baseline at Week 52 | 1.07 ± 0.36 | 0.94 ± 0.36 | 1.04 ± 0.29 | 1.12 ± 0.32 | 1.06 ± 0.32 | 1.00 ± 0.35 |
Change in free fatty acids (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.
| Ratio of FFA | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 16 | 1.52 ± 1.60 | 1.31 ± 0.61 | 1.04 ± 0.35 | 0.99 ± 0.30 | 1.31 ± 1.21 | 1.21 ± 0.55 |
Change in free fatty acids (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.
| Ratio of FFA | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 52 | 1.15 ± 0.76 | 1.45 ± 0.49 | 0.85 ± 0.51 | 1.05 ± 0.25 | 1.01 ± 0.67 | 1.32 ± 0.45 |
Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 16 is presented.
| Millimeters of mercury (mmHg) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| SBP: Change from week 0 to week 16 | -5 ± 15 | -2 ± 13 | 2 ± 9 | 2 ± 6 | -1 ± 13 | -1 ± 11 |
| DBP: Change from week 0 to week 16 | -1 ± 10 | 0 ± 7 | 1 ± 8 | -1 ± 17 | 0 ± 9 | 0 ± 11 |
Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 52 is presented.
| Millimeters of mercury (mmHg) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| SBP: Change from week 0 to week 52 | -5 ± 6 | 4 ± 12 | 4 ± 15 | 7 ± 8 | -1 ± 11 | 5 ± 11 |
| DBP: Change from week 0 to week 52 | -3 ± 9 | 5 ± 13 | 4 ± 13 | 1 ± 7 | 0 ± 11 | 4 ± 12 |
Change in HbA1c from baseline to week 16 is presented.
| Percentage point of HbA1c | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) From Baseline at Week 16 | -0.2 ± 0.1 | 0 ± 0.3 | -0.2 ± 0.3 | -0.2 ± 0.3 | -0.2 ± 0.2 | -0.1 ± 0.3 |
Change in HbA1c from baseline to week 52 is presented.
| Percentage point of HbA1c | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in HbA1c From Baseline at Week 52 | -0.2 ± 0.2 | 0.1 ± 0.3 | -0.2 ± 0.4 | -0.1 ± 0.3 | -0.2 ± 0.3 | 0.1 ± 0.3 |
Change in FPG from baseline to week 16 is presented.
| mmol/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Fasting Plasma Glucose (FPG) From Baseline at Week 16 | -0.2 ± 0.5 | 0.1 ± 0.5 | -0.1 ± 0.5 | 0.2 ± 0.4 | -0.2 ± 0.5 | 0.1 ± 0.4 |
Change in FPG from baseline to week 52 is presented.
| mmol/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in FPG From Baseline at Week 52 | 0 ± 0.7 | 0.3 ± 0.8 | 0 ± 0.4 | 0 ± 0.4 | 0 ± 0.6 | 0.2 ± 0.7 |
Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 16 is presented as ratio to baseline.
| Ratio of fasting insulin | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Fasting Insulin From Baseline at Week 16 | 1.59 ± 1.91 | 0.78 ± 0.32 | 1.43 ± 1.17 | 1.32 ± 0.68 | 1.52 ± 1.62 | 0.97 ± 0.53 |
Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 52 is presented as ratio to baseline.
| Ratio of fasting insulin | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Fasting Insulin From Baseline at Week 52 | 2.03 ± 2.33 | 0.79 ± 0.37 | 1.45 ± 1.27 | 1.22 ± 0.44 | 1.78 ± 1.94 | 0.96 ± 0.44 |
Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 16 is presented as ratio to baseline.
| Ratio of fasting C peptide | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Fasting C Peptide From Baseline at Week 16 | 1.14 ± 0.56 | 0.86 ± 0.20 | 1.11 ± 0.50 | 1.08 ± 0.44 | 1.13 ± 0.53 | 0.94 ± 0.31 |
Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 52 is presented as ratio to baseline.
| Ratio of fasting C peptide | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Fasting C Peptide From Baseline at Week 52 | 1.34 ± 0.92 | 0.91 ± 0.23 | 1.15 ± 0.45 | 1.09 ± 0.30 | 1.26 ± 0.75 | 0.98 ± 0.26 |
Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 16 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \<5.6 mmol/L (\<100 mg/dL) and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.
| Participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Normoglycaemia | 16 | 8 | 11 | 5 | 27 | 13 |
| Pre-diabetes | 2 | 4 | 2 | 2 | 4 | 6 |
| Type 2 diabetes | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes" at Week 52 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \<5.6 mmol/L (\<100 mg/dL) and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.
| Participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Normoglycaemia | 13 | 4 | 10 | 2 | 23 | 6 |
| Pre-diabetes | 2 | 4 | 2 | 3 | 4 | 7 |
| Type 2 diabetes | 1 | 1 | 0 | 0 | 1 | 1 |
Change in HOMA-B from baseline to week 16 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5).
| Ratio of HOMA-B | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 16 | 1.69 ± 1.93 | 0.70 ± 0.31 | 1.55 ± 1.04 | 1.07 ± 0.51 | 1.63 ± 1.59 | 0.82 ± 0.41 |
Change in HOMA-B from baseline to week 52 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5).
| Ratio of HOMA-B | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 52 | 2.24 ± 1.85 | 0.65 ± 0.30 | 1.50 ± 1.50 | 1.25 ± 0.50 | 1.91 ± 1.71 | 0.88 ± 0.48 |
Change in HOMA-IR from baseline to week 16 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose \[mmol/L\] x fasting insulin \[mmol/L\]/ 22.5.
| Ratio of HOMA-IR | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 16 | 1.57 ± 1.92 | 0.80 ± 0.35 | 1.43 ± 1.26 | 1.33 ± 0.82 | 1.51 ± 1.65 | 0.97 ± 0.58 |
Change in HOMA-IR from baseline to week 52 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose \[mmol/L\] x fasting insulin \[mmol/L\]/ 22.5.
| Ratio of HOMA-IR | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 52 | 2.26 ± 3.13 | 0.88 ± 0.50 | 1.45 ± 1.23 | 1.24 ± 0.48 | 1.90 ± 2.46 | 1.02 ± 0.51 |
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or using a medicinal product, whether or not considered related to the medicinal product or usage. All AEs reported here are TEAEs. TEAE is defined as an event that had onset date during the on-treatment period. The endpoint was evaluated based on the data from on-treatment period. On-treatment period included AEs are with an onset date on or after the first day of trial product administration and any of the following dates, whichever came first: a) 14 days after the last day on trial product, or b) Follow-up visit (week 54) for participants with trial product discontinuation, or c) Last study visit (participants withdrawn without follow-up visit (week 54)).
| Events | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Number of Treatment Emergent Adverse Events | 134 | 37 | 159 | 8 | 293 | 45 |
Hypoglycaemic episode (blood glucose less than or equal to (\<=) 3.9 mmol/L (70 mg/dL) Or greater than (\>) 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms) is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Severe hypoglycaemia defined by American Diabetes Association (ADA) 2013 and International Society for Paediatric and Adolescent Diabetes (ISPAD) 2018: hypoglycaemic episode associated with severe cognitive impairment requiring external assistance for recovery. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).
| Episodes | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Number of Severe Treatment Emergent Episodes of Hypoglycaemia | 0 | 0 | 1 | 0 | 1 | 0 |
Symptomatic blood glucose confirmed hypoglycaemia: An episode that is blood glucose confirmed by plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episode is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).
| Episodes | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Number of Blood Glucose Confirmed Symptomatic Episodes of Hypoglycaemia | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with occurrence of anti-liraglutide antibodies is presented. In the below table, 'Yes' infers number of participants with occurrence of anti- liraglutide antibodies and 'No' infers number of participants without anti- liraglutide antibodies.
| Participants | Part A: Liraglutide | Part B: Liraglutide | Part A+B: Liraglutide |
|---|---|---|---|
| Yes | 2 | 1 | 3 |
| No | 14 | 8 | 22 |
A 12-lead ECG was performed at baseline (week 0) and week 16 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and weeks 16 are presented.
| Participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Week 0: Normal | 20 | 12 | 17 | 6 | 37 | 18 |
| Week 0: Abnormal, NCS | 0 | 0 | 0 | 1 | 0 | 1 |
| Week 0: Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 16: Normal | 17 | 12 | 13 | 7 | 30 | 19 |
| Week 16: Abnormal, NCS | 0 | 0 | 1 | 0 | 1 | 0 |
| Week 16: Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
A 12-lead ECG was performed at baseline (week 0) and week 52 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and week 52 are presented.
| Participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Week 0: Normal | 20 | 12 | 17 | 6 | 37 | 18 |
| Week 0: Abnormal, NCS | 0 | 0 | 0 | 1 | 0 | 1 |
| Week 0: Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 52: Normal | 17 | 9 | 13 | 4 | 30 | 13 |
| Week 52: Abnormal, NCS | 1 | 1 | 0 | 0 | 1 | 1 |
| Week 52: Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
Change in pulse from baseline to week 16 is presented.
| Beats/minute | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Pulse From Baseline at Week 16 | 2 ± 12 | -2 ± 5 | 1 ± 16 | -9 ± 10 | 2 ± 14 | -4 ± 8 |
Change in pulse from baseline to week 52 is presented.
| Beats/minute | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Pulse From Baseline at Week 52 | 1 ± 13 | -8 ± 10 | 10 ± 11 | -6 ± 8 | 5 ± 13 | -7 ± 10 |
Change in haemoglobin from baseline to week 16 is presented.
| millimoles per liter (mmol/L) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Haematology: Haemoglobin From Baseline at Week 16 | -0.18 ± 0.43 | 0.06 ± 0.28 | -0.20 ± 1.22 | -0.07 ± 0.55 | -0.19 ± 0.84 | 0.01 ± 0.38 |
Change in haemoglobin from baseline to week 52 is presented.
| mmol/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Haematology: Haemoglobin From Baseline at Week 52 | -0.14 ± 0.79 | -0.01 ± 0.31 | -0.02 ± 0.61 | -0.02 ± 0.20 | -0.09 ± 0.72 | -0.01 ± 0.28 |
Change in haematocrit from baseline to week 16 is presented.
| Percentage of haematocrit in blood | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Haematology: Haematocrit From Baseline at Week 16 | -1.8 ± 2.1 | -0.5 ± 1.3 | 0.4 ± 2.6 | -0.6 ± 3.3 | -0.9 ± 2.6 | -0.5 ± 2.1 |
Change in haematocrit from baseline to week 52 is presented.
| Percentage of haematocrit in blood | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Haematology: Haematocrit From Baseline at Week 52 | -1.4 ± 4.0 | 0 ± 1.7 | -0.2 ± 2.7 | -0.8 ± 2.6 | -0.9 ± 3.5 | -0.3 ± 1.9 |
Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 16 is presented.
| 10^9 cells per liter (10^9/L) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Thrombocytes: Change from week 0 to week 16 | 6 ± 35 | -21 ± 26 | 8 ± 66 | 19 ± 18 | 7 ± 49 | -8 ± 30 |
| Leukocytes: Change from week 0 to week 16 | -0.1 ± 1.5 | -0.3 ± 1.6 | -0.8 ± 2.3 | -1.1 ± 1.7 | -0.4 ± 1.9 | -0.6 ± 1.6 |
| Eosinophils: Change from week 0 to week 16 | -0.03 ± 0.09 | 0.04 ± 0.07 | -0.14 ± 0.27 | 0.07 ± 0.32 | -0.07 ± 0.20 | 0.05 ± 0.19 |
| Neutrophils: Change from week 0 to week 16 | 0.11 ± 1.08 | -0.22 ± 1.62 | -0.28 ± 1.59 | -1.35 ± 1.33 | -0.06 ± 1.31 | -0.62 ± 1.58 |
| Basophils: Change from week 0 to week 16 | -0.01 ± 0.02 | 0 ± 0.02 | -0.01 ± 0.04 | -0.01 ± 0.04 | -0.01 ± 0.03 | 0 ± 0.03 |
| Lymphocytes: Change from week 0 to week 16 | -0.24 ± 0.66 | -0.09 ± 0.97 | -0.36 ± 0.89 | 0.09 ± 0.85 | -0.29 ± 0.76 | -0.02 ± 0.91 |
| Monocytes: Change from week 0 to week 16 | 0.06 ± 0.17 | -0.04 ± 0.12 | -0.05 ± 0.17 | 0.05 ± 0.20 | 0.01 ± 0.18 | -0.01 ± 0.15 |
Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 52 is presented.
| 10^9 cells per liter (10^9/L) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Thrombocytes: Change from week 0 to week 52 | 18 ± 44 | -7 ± 39 | -2 ± 37 | 37 ± 70 | 10 ± 42 | 5 ± 49 |
| Leukocytes: Change from week 0 to week 52 | -0.2 ± 1.1 | -0.6 ± 1.7 | -0.7 ± 2.8 | 0.3 ± 3.0 | -0.4 ± 1.9 | -0.3 ± 2.1 |
| Eosinophils: Change from week 0 to week 52 | 0.01 ± 0.11 | 0.03 ± 0.19 | -0.13 ± 0.36 | -0.17 ± 0.13 | -0.05 ± 0.24 | -0.03 ± 0.20 |
| Neutrophils: Change from week 0 to week 52 | 0.11 ± 1.17 | -0.76 ± 1.40 | -0.03 ± 2.03 | -0.07 ± 2.55 | 0.05 ± 1.53 | -0.55 ± 1.75 |
| Basophils: Change from week 0 to week 52 | 0 ± 0.03 | 0 ± 0.04 | -0.01 ± 0.04 | 0.02 ± 0.04 | -0.01 ± 0.04 | 0.01 ± 0.04 |
| Lymphocytes: Change from week 0 to week 52 | -0.28 ± 0.67 | 0.19 ± 0.70 | -0.47 ± 0.59 | 0.39 ± 0.49 | -0.36 ± 0.63 | 0.25 ± 0.63 |
| Monocytes: Change from week 0 to week 52 | -0.04 ± 0.19 | -0.06 ± 0.22 | -0.05 ± 0.19 | 0.14 ± 0.20 | -0.04 ± 0.19 | 0 ± 0.23 |
Change in erythrocytes from baseline to week 16 is presented.
| 10^12 cells per liter (10^12/L) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Haematology: Erythrocytes From Baseline at Week 16 | -0.1 ± 0.2 | 0 ± 0.2 | 0.1 ± 0.3 | 0 ± 0.3 | -0.1 ± 0.3 | 0 ± 0.2 |
Change in erythrocytes from baseline to week 52 is presented.
| 10^12 cells per liter (10^12/L) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Haematology: Erythrocytes From Baseline at Week 52 | -0.1 ± 0.4 | 0 ± 0.2 | -0.1 ± 0.3 | 0 ± 0 | -0.1 ± 0.4 | 0 ± 0.1 |
Change in creatinine and bilirubin (total) from baseline to week 16 is presented.
| micro mole per liter (umol/L) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Creatinine: Change from week 0 to week 16 | 1 ± 5 | 0 ± 6 | 2 ± 7 | 0 ± 6 | 1 ± 5 | 0 ± 6 |
| Bilirubin (total): Change from week 0 to week 16 | 0 ± 2 | 0 ± 2 | 0 ± 2 | 1 ± 2 | 0 ± 2 | 0 ± 2 |
Change in creatinine and bilirubin (total) from baseline to week 52 is presented.
| umol/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Creatinine: Change from week 0 to week 52 | 3 ± 8 | -4 ± 9 | 3 ± 6 | 5 ± 3 | 3 ± 7 | -1 ± 9 |
| Bilirubin (total): Change from week 0 to week 52 | 0 ± 2 | 2 ± 3 | 0 ± 1 | 2 ± 3 | 0 ± 2 | 2 ± 3 |
Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 16 is presented.
| Units per liter (U/L) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Creatinine kinase: Change from week 0 to week 16 | -3 ± 37 | 16 ± 45 | 3 ± 23 | -5 ± 5 | -1 ± 32 | 10 ± 39 |
| Amylase: Change from week 0 to week 16 | 5 ± 13 | -2 ± 5 | 8 ± 12 | 8 ± 8 | 6 ± 13 | 1 ± 8 |
| Lipase: Change from week 0 to week 16 | 10 ± 6 | 0 ± 4 | 8 ± 7 | 1 ± 2 | 9 ± 6 | 0 ± 3 |
| ALT: Change from week 0 to week 16 | -9 ± 32 | -4 ± 18 | -2 ± 6 | -25 ± 23 | -6 ± 25 | -10 ± 21 |
| AST: Change from week 0 to week 16 | -6 ± 14 | 0 ± 10 | -2 ± 5 | -18 ± 24 | -4 ± 11 | -6 ± 17 |
| ALP: Change from week 0 to week 16 | -10 ± 12 | -7 ± 25 | -21 ± 36 | -47 ± 42 | -14 ± 24 | -19 ± 35 |
Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 52 is presented.
| Units per liter (U/L) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Creatinine kinase: Change from week 0 to week 52 | 30 ± 206 | -4 ± 29 | 25 ± 42 | -8 ± 25 | 28 ± 159 | -5 ± 27 |
| Amylase: Change from week 0 to week 52 | 4 ± 10 | 2 ± 12 | 7 ± 12 | 8 ± 5 | 5 ± 11 | 4 ± 11 |
| Lipase: Change from week 0 to week 52 | 9 ± 9 | -1 ± 3 | 7 ± 6 | 3 ± 5 | 8 ± 8 | 0 ± 4 |
| ALT: Change from week 0 to week 52 | 1 ± 12 | 4 ± 25 | 0 ± 16 | -24 ± 28 | 1 ± 14 | -6 ± 29 |
| AST: Change from week 0 to week 52 | -2 ± 7 | 9 ± 31 | 1 ± 7 | -21 ± 32 | -1 ± 7 | 0 ± 33 |
| ALP: Change from week 0 to week 52 | -24 ± 27 | -35 ± 27 | -25 ± 59 | -26 ± 60 | -24 ± 42 | -32 ± 39 |
Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 16 is presented.
| mmol/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Urea: Change from week 0 to week 16 | 0.03 ± 1.45 | -0.51 ± 0.67 | 0 ± 0.99 | 0.09 ± 2.19 | 0.02 ± 1.26 | -0.31 ± 1.33 |
| Sodium: Change from week 0 to week 16 | 0 ± 5 | 2 ± 3 | 1 ± 4 | 0 ± 1 | 0 ± 4 | 1 ± 3 |
| Potassium: Change from week 0 to week 16 | 0.1 ± 0.4 | -0.1 ± 0.3 | -0.2 ± 0.6 | -0.1 ± 0.2 | 0 ± 0.5 | -0.1 ± 0.2 |
| Calcium: Change from week 0 to week 16 | 0 ± 0.12 | 0 ± 0.10 | 0.08 ± 0.17 | 0.02 ± 0.10 | 0.03 ± 0.14 | 0.01 ± 0.10 |
Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 52 is presented.
| mmol/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Urea: Change from week 0 to week 52 | -0.38 ± 1.56 | -0.34 ± 0.54 | -0.21 ± 1.00 | -0.04 ± 1.08 | -0.31 ± 1.34 | -0.24 ± 0.74 |
| Sodium: Change from week 0 to week 52 | -1 ± 5 | -2 ± 5 | 1 ± 4 | 2 ± 2 | 0 ± 4 | -1 ± 4 |
| Potassium: Change from week 0 to week 52 | -0.2 ± 0.6 | -0.1 ± 0.2 | -0.2 ± 0.7 | 0 ± 0.2 | -0.2 ± 0.6 | -0.1 ± 0.2 |
| Calcium: Change from week 0 to week 52 | -0.05 ± 0.14 | -0.11 ± 0.12 | 0.09 ± 0.14 | 0 ± 0.02 | 0.01 ± 0.15 | -0.08 ± 0.11 |
Change in albumin from baseline to week 16 is presented.
| gram per deciliter (g/dL) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Biochemistry: Albumin From Baseline at Week 16 | 0 ± 0.2 | 0 ± 0.1 | 0 ± 0.2 | 0 ± 0.1 | 0 ± 0.2 | 0 ± 0.1 |
Change in albumin from baseline to week 52 is presented.
| g/dL | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Biochemistry: Albumin From Baseline at Week 52 | -0.1 ± 0.7 | -0.1 ± 0.3 | 0 ± 0.2 | 0 ± 0.1 | 0 ± 0.5 | -0.1 ± 0.2 |
Change in CEA serum from baseline to week 16 is presented.
| nanogram per milliliter (ng/mL) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 16 | -0.01 ± 0.11 | -0.17 ± 0.30 | 0.17 ± 0.55 | -0.04 ± 0.10 | 0.07 ± 0.38 | -0.12 ± 0.24 |
Change in CEA serum from baseline to week 52 is presented.
| ng/mL | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 52 | 0.03 ± 0.38 | -0.14 ± 0.26 | -0.01 ± 0.14 | 0.17 ± 0.24 | 0.01 ± 0.29 | -0.01 ± 0.29 |
Change in calcitonin from baseline to week 16 is presented.
| nanogram per liter (ng/L) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Hormone Level: Calcitonin From Baseline at Week 16 | 0 ± 0 | 0 ± 0 | 0.3 ± 1.1 | 0 ± 0 | 0.1 ± 0.7 | 0 ± 0 |
Change in calcitonin from baseline to week 52 is presented.
| ng/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Hormone Level: Calcitonin From Baseline at Week 52 | 0.1 ± 0.6 | 0 ± 0 | 0.5 ± 1.2 | 0 ± 0 | 0.3 ± 0.9 | 0 ± 0 |
Change in TSH and prolactin from baseline to week 16 is presented.
| Milli-international units/liter (mIU/L) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| TSH: Change from week 0 to week 16 | -0.34 ± 0.68 | -0.01 ± 0.72 | -0.09 ± 1.13 | -0.59 ± 0.67 | -0.23 ± 0.89 | -0.23 ± 0.74 |
| Prolactin: Change from week 0 to week 16 | 7 ± 27 | -6 ± 33 | 0 ± 13 | -22 ± 63 | 4 ± 22 | -12 ± 45 |
Change in TSH and prolactin from baseline to week 52 is presented.
| mIU/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| TSH: Change from week 0 to week 52 | 0.02 ± 1.59 | -0.48 ± 0.63 | -0.75 ± 2.13 | -0.17 ± 1.08 | -0.30 ± 1.83 | -0.38 ± 0.78 |
| Prolactin: Change from week 0 to week 52 | 10 ± 38 | 8 ± 37 | -3 ± 37 | 29 ± 33 | 5 ± 37 | 15 ± 36 |
Change in free T4 and ACTH from baseline to week 16 is presented.
| picomole per liter (pmol/L) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| T4: Change from week 0 to week 16 | -0.6 ± 1.4 | 0.3 ± 1.1 | 0.7 ± 2.3 | 0.1 ± 1.7 | -0.1 ± 1.9 | 0.2 ± 1.3 |
| ACTH: Change from week 0 to week 16 | 0.99 ± 5.22 | -0.85 ± 2.22 | -0.37 ± 1.49 | -1.32 ± 1.87 | 0.42 ± 4.10 | -1.02 ± 2.04 |
Change in free T4 and ACTH from baseline to week 52 is presented.
| pmol/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| T4: Change from week 0 to week 52 | -0.4 ± 1.7 | 1.9 ± 2.7 | -0.1 ± 2.0 | 0.8 ± 2.3 | -0.3 ± 1.8 | 1.5 ± 2.5 |
| ACTH: Change from week 0 to week 52 | -0.02 ± 2.02 | 1.29 ± 3.50 | 0.98 ± 5.64 | 0.20 ± 2.41 | 0.42 ± 3.99 | 0.89 ± 3.07 |
Change in IGF-1 and cortisol from baseline to week 16 is presented.
| nanogram per milliliter (ng/mL) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| IGF-1: Change from week 0 to week 16 | -56.89 ± 126.46 | -28.23 ± 95.79 | 2.41 ± 84.98 | -14.23 ± 75.01 | -30.31 ± 112.09 | -23.86 ± 87.54 |
| Cortisol: Change from week 0 to week 16 | -22.94 ± 41.36 | 6.75 ± 38.72 | -8.09 ± 22.98 | -23.08 ± 59.02 | -16.71 ± 35.16 | -4.85 ± 48.33 |
Change in IGF-1 and cortisol from baseline to week 52 is presented.
| ng/mL | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| IGF-1: Change from week 0 to week 52 | -25.90 ± 195.61 | -103.45 ± 136.61 | -1.47 ± 112.93 | 10.40 ± 56.69 | -15.04 ± 161.72 | -59.66 ± 123.62 |
| Cortisol: Change from week 0 to week 52 | 3.60 ± 50.63 | 7.54 ± 33.71 | -14.15 ± 43.84 | 21.67 ± 46.62 | -4.01 ± 47.82 | 12.59 ± 37.65 |
Change in DHEAS from baseline to week 16 is presented.
| umol/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 16 | 0.16 ± 1.74 | 0.21 ± 0.95 | 0.25 ± 1.10 | 1.00 ± 1.42 | 0.20 ± 1.48 | 0.46 ± 1.13 |
Change in DHEAS from baseline to week 52 is presented.
| umol/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 52 | 0.77 ± 1.18 | 0.76 ± 0.97 | 0.25 ± 0.66 | 0.74 ± 1.26 | 0.55 ± 1.01 | 0.76 ± 1.01 |
Change in LH and FSH from baseline to week 16 is presented.
| IU/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| LH: Change from week 0 to week 16 | -0.04 ± 1.28 | 0.06 ± 0.74 | -0.07 ± 0.25 | 0.22 ± 0.42 | -0.05 ± 0.97 | 0.12 ± 0.63 |
| FSH: Change from week 0 to week 16 | -0.2 ± 2.5 | 0.2 ± 1.0 | -0.1 ± 1.3 | 1.0 ± 1.1 | -0.2 ± 2.1 | 0.5 ± 1.1 |
Change in LH and FSH from baseline to week 52 is presented.
| IU/L | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| LH: Change from week 0 to week 52 | 0.16 ± 2.33 | 0.06 ± 0.79 | 0.37 ± 0.96 | 0.30 ± 0.51 | 0.24 ± 1.87 | 0.14 ± 0.70 |
| FSH: Change from week 0 to week 52 | 1.1 ± 3.9 | 0.4 ± 1.6 | 0.4 ± 1.8 | 0.7 ± 1.6 | 0.8 ± 3.1 | 0.6 ± 1.5 |
Change in estradiol (only for females) from baseline to week 16 is presented.
| picograms per milliliter (pg/mL) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Hormone Level: Estradiol (Females) From Baseline at Week 16 | 0.9 ± 15.8 | 9.2 ± 11.9 | 1.6 ± 3.8 | 0 ± 0 | 1.2 ± 12.2 | 6.1 ± 10.4 |
Change in estradiol (only for females) from baseline to week 52 is presented.
| pg/mL | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Change in Hormone Level: Estradiol (Females) From Baseline at Week 52 | 7.0 ± 32.6 | 13.7 ± 21.6 | 1.6 ± 4.5 | 0 ± NA | 4.1 ± 21.8 | 11.0 ± 19.7 |
Change in testosterone (only for males) from baseline to week 16 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.
| nanomoles per liter (nmol/L) | Part A: Liraglutide | Part A: Placebo |
|---|---|---|
| Change in Hormone Level: Testosterone (Males) From Baseline at Week 16 | 1.55 ± 2.01 | 0.61 ± 1.66 |
Change in testosterone (only for males) from baseline to week 52 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.
| nmol/L | Part A: Liraglutide | Part A: Placebo |
|---|---|---|
| Change in Hormone Level: Testosterone (Males) From Baseline at Week 52 | 0.62 ± 1.40 | -0.34 ± 1.51 |
This outcome measure presents "pubertal status results" which is based on Tanner staging recorded at baseline (week 0), week 16. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult".
| Participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Week 0: Breast development (for female) — Stage 1 | 0 | 0 | 11 | 2 | 11 | 2 |
| Week 0: Breast development (for female) — Stage 2 | 1 | 0 | 0 | 0 | 1 | 0 |
| Week 0: Breast development (for female) — Stage 3 | 8 | 2 | 0 | 0 | 8 | 2 |
| Week 0: Breast development (for female) — Stage 4 | 0 | 1 | 0 | 0 | 0 | 1 |
| Week 0: Breast development (for female) — Stage 5 | 2 | 2 | 0 | 0 | 2 | 2 |
| Week 16: Breast development (for female) — Stage 1 | 0 | 0 | 6 | 2 | 6 | 2 |
| Week 16: Breast development (for female) — Stage 2 | 1 | 0 | 3 | 0 | 4 | 0 |
| Week 16: Breast development (for female) — Stage 3 | 7 | 1 | 0 | 0 | 7 | 1 |
| Week 16: Breast development (for female) — Stage 4 | 0 | 2 | 0 | 0 | 0 | 2 |
| Week 16: Breast development (for female) — Stage 5 | 2 | 2 | 0 | 0 | 2 | 2 |
| Week 0: Pubic hair development (for female) — Stage 1 | 1 | 0 | 6 | 1 | 7 | 1 |
| Week 0: Pubic hair development (for female) — Stage 2 | 2 | 0 | 3 | 0 | 5 | 0 |
| Week 0: Pubic hair development (for female) — Stage 3 | 3 | 2 | 0 | 1 | 3 | 3 |
| Week 0: Pubic hair development (for female) — Stage 4 | 3 | 1 | 2 | 0 | 5 | 1 |
| Week 0: Pubic hair development (for female) — Stage 5 | 2 | 2 | 0 | 0 | 2 | 2 |
| Week 16: Pubic hair development (for female) — Stage 1 | 1 | 0 | 3 | 1 | 4 | 1 |
| Week 16: Pubic hair development (for female) — Stage 2 | 1 | 0 | 5 | 0 | 6 | 0 |
| Week 16: Pubic hair development (for female) — Stage 3 | 4 | 1 | 0 | 1 | 4 | 2 |
| Week 16: Pubic hair development (for female) — Stage 4 | 2 | 2 | 1 | 0 | 3 | 2 |
| Week 16: Pubic hair development (for female) — Stage 5 | 2 | 2 | 0 | 0 | 2 | 2 |
| Week 0: Pubic hair development (for male) — Stage 1 | 0 | 0 | 6 | 3 | 6 | 3 |
| Week 0: Pubic hair development (for male) — Stage 2 | 3 | 0 | 0 | 1 | 3 | 1 |
| Week 0: Pubic hair development (for male) — Stage 3 | 2 | 4 | 0 | 1 | 2 | 5 |
| Week 0: Pubic hair development (for male) — Stage 4 | 2 | 2 | 0 | 0 | 2 | 2 |
| Week 0: Pubic hair development (for male) — Stage 5 | 2 | 1 | 0 | 0 | 2 | 1 |
| Week 16: Pubic hair development (for male) — Stage 1 | 0 | 0 | 6 | 1 | 6 | 1 |
| Week 16: Pubic hair development (for male) — Stage 2 | 2 | 0 | 0 | 3 | 2 | 3 |
| Week 16: Pubic hair development (for male) — Stage 3 | 2 | 3 | 0 | 1 | 2 | 4 |
| Week 16: Pubic hair development (for male) — Stage 4 | 2 | 2 | 0 | 0 | 2 | 2 |
| Week 16: Pubic hair development (for male) — Stage 5 | 3 | 2 | 0 | 0 | 3 | 2 |
| Week 0: Penis development (for male) — Stage 1 | 0 | 1 | 6 | 5 | 6 | 6 |
| Week 0: Penis development (for male) — Stage 2 | 4 | 3 | 0 | 0 | 4 | 3 |
| Week 0: Penis development (for male) — Stage 3 | 1 | 1 | 0 | 0 | 1 | 1 |
| Week 0: Penis development (for male) — Stage 4 | 3 | 2 | 0 | 0 | 3 | 2 |
| Week 0: Penis development (for male) — Stage 5 | 1 | 0 | 0 | 0 | 1 | 0 |
| Week 16: Penis development (for male) — Stage 1 | 0 | 1 | 5 | 5 | 5 | 6 |
| Week 16: Penis development (for male) — Stage 2 | 2 | 1 | 1 | 0 | 3 | 1 |
| Week 16: Penis development (for male) — Stage 3 | 2 | 3 | 0 | 0 | 2 | 3 |
| Week 16: Penis development (for male) — Stage 4 | 2 | 1 | 0 | 0 | 2 | 1 |
| Week 16: Penis development (for male) — Stage 5 | 3 | 1 | 0 | 0 | 3 | 1 |
This outcome measure presents "pubertal status results" which is based on Tanner staging recorded at baseline (week 0) and week 52. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult".
| Participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Week 0: Breast development (for female) — Stage 1 | 0 | 0 | 11 | 2 | 11 | 2 |
| Week 0: Breast development (for female) — Stage 2 | 1 | 0 | 0 | 0 | 1 | 0 |
| Week 0: Breast development (for female) — Stage 3 | 8 | 2 | 0 | 0 | 8 | 2 |
| Week 0: Breast development (for female) — Stage 4 | 0 | 1 | 0 | 0 | 0 | 1 |
| Week 0: Breast development (for female) — Stage 5 | 2 | 2 | 0 | 0 | 2 | 2 |
| Week 52: Breast development (for female) — Stage 1 | 0 | 0 | 2 | 1 | 2 | 1 |
| Week 52: Breast development (for female) — Stage 2 | 0 | 0 | 4 | 0 | 4 | 0 |
| Week 52: Breast development (for female) — Stage 3 | 5 | 1 | 2 | 0 | 7 | 1 |
| Week 52: Breast development (for female) — Stage 4 | 1 | 2 | 0 | 0 | 1 | 2 |
| Week 52: Breast development (for female) — Stage 5 | 3 | 2 | 0 | 0 | 3 | 2 |
| Week 0: Pubic hair development (for female) — Stage 1 | 1 | 0 | 6 | 1 | 7 | 1 |
| Week 0: Pubic hair development (for female) — Stage 2 | 2 | 0 | 3 | 0 | 5 | 0 |
| Week 0: Pubic hair development (for female) — Stage 3 | 3 | 2 | 0 | 1 | 3 | 3 |
| Week 0: Pubic hair development (for female) — Stage 4 | 3 | 1 | 2 | 0 | 5 | 1 |
| Week 0: Pubic hair development (for female) — Stage 5 | 2 | 2 | 0 | 0 | 2 | 2 |
| Week 52: Pubic hair development (for female) — Stage 1 | 1 | 0 | 1 | 0 | 2 | 0 |
| Week 52: Pubic hair development (for female) — Stage 2 | 1 | 0 | 2 | 0 | 3 | 0 |
| Week 52: Pubic hair development (for female) — Stage 3 | 2 | 1 | 4 | 1 | 6 | 2 |
| Week 52: Pubic hair development (for female) — Stage 4 | 3 | 2 | 1 | 0 | 4 | 2 |
| Week 52: Pubic hair development (for female) — Stage 5 | 2 | 2 | 0 | 0 | 2 | 2 |
| Week 0: Pubic hair development (for male) — Stage 1 | 0 | 0 | 6 | 3 | 6 | 3 |
| Week 0: Pubic hair development (for male) — Stage 2 | 3 | 0 | 0 | 1 | 3 | 1 |
| Week 0: Pubic hair development (for male) — Stage 3 | 2 | 4 | 0 | 1 | 2 | 5 |
| Week 0: Pubic hair development (for male) — Stage 4 | 2 | 2 | 0 | 0 | 2 | 2 |
| Week 0: Pubic hair development (for male) — Stage 5 | 2 | 1 | 0 | 0 | 2 | 1 |
| Week 52: Pubic hair development (for male) — Stage 1 | 0 | 0 | 4 | 0 | 4 | 0 |
| Week 52: Pubic hair development (for male) — Stage 2 | 0 | 0 | 1 | 1 | 1 | 1 |
| Week 52: Pubic hair development (for male) — Stage 3 | 3 | 2 | 0 | 1 | 3 | 3 |
| Week 52: Pubic hair development (for male) — Stage 4 | 3 | 3 | 0 | 1 | 3 | 4 |
| Week 52: Pubic hair development (for male) — Stage 5 | 3 | 1 | 0 | 0 | 3 | 1 |
| Week 0: Penis development (for male) — Stage 1 | 0 | 1 | 6 | 5 | 6 | 6 |
| Week 0: Penis development (for male) — Stage 2 | 4 | 3 | 0 | 0 | 4 | 3 |
| Week 0: Penis development (for male) — Stage 3 | 1 | 1 | 0 | 0 | 1 | 1 |
| Week 0: Penis development (for male) — Stage 4 | 3 | 2 | 0 | 0 | 3 | 2 |
| Week 0: Penis development (for male) — Stage 5 | 1 | 0 | 0 | 0 | 1 | 0 |
| Week 52: Penis development (for male) — Stage 1 | 0 | 1 | 3 | 2 | 3 | 3 |
| Week 52: Penis development (for male) — Stage 2 | 1 | 1 | 2 | 1 | 3 | 2 |
| Week 52: Penis development (for male) — Stage 3 | 2 | 1 | 0 | 0 | 2 | 1 |
| Week 52: Penis development (for male) — Stage 4 | 3 | 2 | 0 | 0 | 3 | 2 |
| Week 52: Penis development (for male) — Stage 5 | 3 | 1 | 0 | 0 | 3 | 1 |
This outcome measure presents number of participants with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0), week 16. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.
| Participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| General Appearance: Week 0 — Normal | 14 | 10 | 12 | 5 | 26 | 15 |
| General Appearance: Week 0 — Abnormal, NCS | 2 | 1 | 3 | 1 | 5 | 2 |
| General Appearance: Week 0 — Abnormal, CS | 4 | 1 | 2 | 1 | 6 | 2 |
| General Appearance: Week 16 — Normal | 14 | 11 | 11 | 5 | 25 | 16 |
| General Appearance: Week 16 — Abnormal, NCS | 1 | 0 | 4 | 1 | 5 | 1 |
| General Appearance: Week 16 — Abnormal, CS | 4 | 1 | 0 | 1 | 4 | 2 |
| Head, ears, eyes, nose, throat, neck: Week 0 — Normal | 19 | 10 | 15 | 6 | 34 | 16 |
| Head, ears, eyes, nose, throat, neck: Week 0 — Abnormal, NCS | 1 | 2 | 2 | 1 | 3 | 3 |
| Head, ears, eyes, nose, throat, neck: Week 0 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Head, ears, eyes, nose, throat, neck: Week 16 — Normal | 18 | 12 | 15 | 7 | 33 | 19 |
| Head, ears, eyes, nose, throat, neck: Week 16 — Abnormal, NCS | 1 | 0 | 0 | 0 | 1 | 0 |
| Head, ears, eyes, nose, throat, neck: Week 16 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Respiratory system: Week 0 — Normal | 20 | 12 | 16 | 7 | 36 | 19 |
| Respiratory system: Week 0 — Abnormal, NCS | 0 | 0 | 1 | 0 | 1 | 0 |
| Respiratory system: Week 0 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Respiratory system: Week 16 — Normal | 19 | 12 | 15 | 7 | 34 | 19 |
| Respiratory system: Week 16 — Abnormal, NCS | 0 | 0 | 0 | 0 | 0 | 0 |
| Respiratory system: Week 16 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Cardiovascular system: Week 0 — Normal | 19 | 12 | 17 | 7 | 36 | 19 |
| Cardiovascular system: Week 0 — Abnormal, NCS | 1 | 0 | 0 | 0 | 1 | 0 |
| Cardiovascular system: Week 0 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Cardiovascular system: Week 16 — Normal | 18 | 12 | 15 | 7 | 33 | 19 |
| Cardiovascular system: Week 16 — Abnormal, NCS | 1 | 0 | 0 | 0 | 1 | 0 |
| Cardiovascular system: Week 16 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| GI system including mouth: Week 0 — Normal | 19 | 12 | 17 | 7 | 36 | 19 |
| GI system including mouth: Week 0 — Abnormal, NCS | 1 | 0 | 0 | 0 | 1 | 0 |
| GI system including mouth: Week 0 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| GI system including mouth: Week 16 — Normal | 17 | 12 | 15 | 7 | 32 | 19 |
| GI system including mouth: Week 16 — Abnormal, NCS | 2 | 0 | 0 | 0 | 2 | 0 |
| GI system including mouth: Week 16 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Musculoskeletal system: Week 0 — Normal | 15 | 9 | 14 | 6 | 29 | 15 |
| Musculoskeletal system: Week 0 — Abnormal, NCS | 3 | 2 | 3 | 1 | 6 | 3 |
| Musculoskeletal system: Week 0 — Abnormal, CS | 2 | 1 | 0 | 0 | 2 | 1 |
| Musculoskeletal system: Week 16 — Normal | 16 | 9 | 11 | 6 | 27 | 15 |
| Musculoskeletal system: Week 16 — Abnormal, NCS | 2 | 1 | 4 | 1 | 6 | 2 |
| Musculoskeletal system: Week 16 — Abnormal, CS | 1 | 2 | 0 | 0 | 1 | 2 |
| CNS and PNS: Week 0 — Normal | 16 | 10 | 15 | 6 | 31 | 16 |
| CNS and PNS: Week 0 — Abnormal, NCS | 2 | 0 | 1 | 1 | 3 | 1 |
| CNS and PNS: Week 0 — Abnormal, CS | 2 | 2 | 1 | 0 | 3 | 2 |
| CNS and PNS: Week 16 — Normal | 15 | 11 | 14 | 7 | 29 | 18 |
| CNS and PNS: Week 16 — Abnormal, NCS | 2 | 0 | 1 | 0 | 3 | 0 |
| CNS and PNS: Week 16 — Abnormal, CS | 2 | 1 | 0 | 0 | 2 | 1 |
| Skin: Week 0 — Normal | 11 | 7 | 10 | 6 | 21 | 13 |
| Skin: Week 0 — Abnormal, NCS | 6 | 4 | 6 | 1 | 12 | 5 |
| Skin: Week 0 — Abnormal, CS | 3 | 1 | 1 | 0 | 4 | 1 |
| Skin: Week 16 — Normal | 12 | 8 | 10 | 6 | 22 | 14 |
| Skin: Week 16 — Abnormal, NCS | 5 | 3 | 5 | 0 | 10 | 3 |
| Skin: Week 16 — Abnormal, CS | 2 | 1 | 0 | 1 | 2 | 2 |
| Thyroid gland: Week 0 — Normal | 20 | 12 | 17 | 7 | 37 | 19 |
| Thyroid gland: Week 0 — Abnormal, NCS | 0 | 0 | 0 | 0 | 0 | 0 |
| Thyroid gland: Week 0 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Thyroid gland: Week 16 — Normal | 19 | 12 | 15 | 7 | 34 | 19 |
| Thyroid gland: Week 16 — Abnormal, NCS | 0 | 0 | 0 | 0 | 0 | 0 |
| Thyroid gland: Week 16 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymph node palpation: Week 0 — Normal | 19 | 12 | 17 | 7 | 36 | 19 |
| Lymph node palpation: Week 0 — Abnormal, NCS | 1 | 0 | 0 | 0 | 1 | 0 |
| Lymph node palpation: Week 0 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymph node palpation: Week 16 — Normal | 19 | 12 | 15 | 7 | 34 | 19 |
| Lymph node palpation: Week 16 — Abnormal, NCS | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymph node palpation: Week 16 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
This outcome measure presents number of participants with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0) and week 52. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.
| Participants | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| General Appearance: Week 0 — Normal | 14 | 10 | 12 | 5 | 26 | 15 |
| General Appearance: Week 0 — Abnormal, NCS | 2 | 1 | 3 | 1 | 5 | 2 |
| General Appearance: Week 0 — Abnormal, CS | 4 | 1 | 2 | 1 | 6 | 2 |
| General Appearance: Week 52 — Normal | 13 | 10 | 9 | 5 | 22 | 15 |
| General Appearance: Week 52 — Abnormal, NCS | 1 | 0 | 2 | 0 | 3 | 0 |
| General Appearance: Week 52 — Abnormal, CS | 3 | 1 | 1 | 0 | 4 | 1 |
| Head, ears, eyes, nose, throat, neck: Week 0 — Normal | 19 | 10 | 15 | 6 | 34 | 16 |
| Head, ears, eyes, nose, throat, neck: Week 0 — Abnormal, NCS | 1 | 2 | 2 | 1 | 3 | 3 |
| Head, ears, eyes, nose, throat, neck: Week 0 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Head, ears, eyes, nose, throat, neck: Week 52 — Normal | 15 | 11 | 12 | 4 | 27 | 15 |
| Head, ears, eyes, nose, throat, neck: Week 52 — Abnormal, NCS | 2 | 0 | 0 | 1 | 2 | 1 |
| Head, ears, eyes, nose, throat, neck: Week 52 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Respiratory system: Week 0 — Normal | 20 | 12 | 16 | 7 | 36 | 19 |
| Respiratory system: Week 0 — Abnormal, NCS | 0 | 0 | 1 | 0 | 1 | 0 |
| Respiratory system: Week 0 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Cardiovascular system: Week 0 — Normal | 19 | 12 | 17 | 7 | 36 | 19 |
| Cardiovascular system: Week 0 — Abnormal, NCS | 1 | 0 | 0 | 0 | 1 | 0 |
| Cardiovascular system: Week 0 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Cardiovascular system: Week 52 — Normal | 17 | 10 | 12 | 5 | 29 | 15 |
| Cardiovascular system: Week 52 — Abnormal, NCS | 0 | 0 | 0 | 0 | 0 | 0 |
| Cardiovascular system: Week 52 — Abnormal, CS | 0 | 1 | 0 | 0 | 0 | 1 |
| GI system including mouth: Week 0 — Normal | 19 | 12 | 17 | 7 | 36 | 19 |
| GI system including mouth: Week 0 — Abnormal, NCS | 1 | 0 | 0 | 0 | 1 | 0 |
| GI system including mouth: Week 0 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| GI system including mouth: Week 52 — Normal | 16 | 11 | 12 | 5 | 28 | 16 |
| GI system including mouth: Week 52 — Abnormal, NCS | 1 | 0 | 0 | 0 | 1 | 0 |
| GI system including mouth: Week 52 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Musculoskeletal system: Week 0 — Normal | 15 | 9 | 14 | 6 | 29 | 15 |
| Musculoskeletal system: Week 0 — Abnormal, NCS | 3 | 2 | 3 | 1 | 6 | 3 |
| Musculoskeletal system: Week 0 — Abnormal, CS | 2 | 1 | 0 | 0 | 2 | 1 |
| Musculoskeletal system: Week 52 — Normal | 15 | 10 | 10 | 5 | 25 | 15 |
| Musculoskeletal system: Week 52 — Abnormal, NCS | 1 | 1 | 2 | 0 | 3 | 1 |
| Musculoskeletal system: Week 52 — Abnormal, CS | 1 | 0 | 0 | 0 | 1 | 0 |
| CNS and PNS: Week 0 — Normal | 16 | 10 | 15 | 6 | 31 | 16 |
| CNS and PNS: Week 0 — Abnormal, NCS | 2 | 0 | 1 | 1 | 3 | 1 |
| CNS and PNS: Week 0 — Abnormal, CS | 2 | 2 | 1 | 0 | 3 | 2 |
| CNS and PNS: Week 52 — Normal | 13 | 10 | 11 | 4 | 24 | 14 |
| CNS and PNS: Week 52 — Abnormal, NCS | 1 | 0 | 0 | 1 | 1 | 1 |
| CNS and PNS: Week 52 — Abnormal, CS | 2 | 1 | 1 | 0 | 3 | 1 |
| Skin: Week 0 — Normal | 11 | 7 | 10 | 6 | 21 | 13 |
| Skin: Week 0 — Abnormal, NCS | 6 | 4 | 6 | 1 | 12 | 5 |
| Skin: Week 0 — Abnormal, CS | 3 | 1 | 1 | 0 | 4 | 1 |
| Skin: Week 52 — Normal | 13 | 8 | 9 | 4 | 22 | 12 |
| Skin: Week 52 — Abnormal, NCS | 3 | 2 | 3 | 0 | 6 | 2 |
| Skin: Week 52 — Abnormal, CS | 1 | 1 | 0 | 1 | 1 | 2 |
| Thyroid gland: Week 0 — Normal | 20 | 12 | 17 | 7 | 37 | 19 |
| Thyroid gland: Week 0 — Abnormal, NCS | 0 | 0 | 0 | 0 | 0 | 0 |
| Thyroid gland: Week 0 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Thyroid gland: Week 52 — Normal | 17 | 11 | 12 | 5 | 29 | 16 |
| Thyroid gland: Week 52 — Abnormal, NCS | 0 | 0 | 0 | 0 | 0 | 0 |
| Thyroid gland: Week 52 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymph node palpation: Week 0 — Normal | 19 | 12 | 17 | 7 | 36 | 19 |
| Lymph node palpation: Week 0 — Abnormal, NCS | 1 | 0 | 0 | 0 | 1 | 0 |
| Lymph node palpation: Week 0 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymph node palpation: Week 52 — Normal | 17 | 11 | 12 | 5 | 29 | 16 |
| Lymph node palpation: Week 52 — Abnormal, NCS | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymph node palpation: Week 52 — Abnormal, CS | 0 | 0 | 0 | 0 | 0 | 0 |
Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Weeks 16 is presented.
| Centimeters/year (cm/yr) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Height Velocity at Week 16 | 2.113 ± 3.084 | 2.718 ± 4.281 | 4.190 ± 2.604 | 6.898 ± 2.886 | 3.090 ± 3.014 | 4.258 ± 4.274 |
Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Week 52 are presented.
| Centimeters/year (cm/yr) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Part A+B: Liraglutide | Part A+B: Placebo |
|---|---|---|---|---|---|---|
| Height Velocity at Week 52 | 1.564 ± 1.285 | 1.839 ± 1.658 | 4.752 ± 2.250 | 5.620 ± 1.690 | 3.004 ± 2.383 | 3.173 ± 2.466 |
C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \[C-CASA\]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is "yes" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is "yes" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with "suicidal ideation or suicidal behaviour on C-SSRS" assessed at baseline (week 0), week 16. The questionnaire was not used in Part B due to the young age of the participants in Part B.
| Participants | Part A: Liraglutide | Part A: Placebo |
|---|---|---|
| Week 0: Suicidal ideation | 1 | 3 |
| Week 0: Suicidal behaviour | 0 | 0 |
| Week 16: Suicidal ideation | 1 | 1 |
| Week 16: Suicidal behaviour | 0 | 0 |
C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \[C-CASA\]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is "yes" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is "yes" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with "suicidal ideation or suicidal behaviour on C-SSRS" assessed at baseline (week 0), week 52. The questionnaire was not used in Part B due to the young age of the participants in Part B.
| Participants | Part A: Liraglutide | Part A: Placebo |
|---|---|---|
| Week 0: Suicidal ideation | 1 | 3 |
| Week 0: Suicidal behaviour | 0 | 0 |
| Week 52: Suicidal ideation | 1 | 0 |
| Week 52: Suicidal behaviour | 0 | 0 |
Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 16. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.
| Score on a scale | Part A: Liraglutide | Part A: Placebo |
|---|---|---|
| Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 16 | -2 ± 4 | 1 ± 5 |
Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 52. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.
| Score on a scale | Part A: Liraglutide | Part A: Placebo |
|---|---|---|
| Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 52 | -2 ± 3 | 0 ± 3 |
Collected over From week 0 to week 54 Results are based on SAS which included all participants exposed to at least one dose of trial product. All AEs reported here are TEAEs. TEAE is as an event that had onset date during on-treatment period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Liraglutide | 0/20 (0%) | 1/20 (5%) | 16/20 (80%) |
| Part B: Liraglutide | 0/17 (0%) | 2/17 (11.8%) | 17/17 (100%) |
| Part A: Placebo | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Part B: Placebo | 0/7 (0%) | 1/7 (14.3%) | 4/7 (57.1%) |
| Event | Part A: Liraglutide | Part B: Liraglutide | Part A: Placebo | Part B: Placebo |
|---|---|---|---|---|
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/20 | 0/17 | 0/12 | 1/7 |
| ArthrodesisSurgical and medical procedures | 0/20 | 1/17 | 0/12 | 0/7 |
| HyperthermiaGeneral disorders | 0/20 | 1/17 | 0/12 | 0/7 |
| Spinal operationSurgical and medical procedures | 0/20 | 1/17 | 0/12 | 0/7 |
| Staphylococcal infectionInfections and infestations | 0/20 | 1/17 | 0/12 | 0/7 |
| CholelithiasisHepatobiliary disorders | 1/20 | 0/17 | 0/12 | 0/7 |
| Event | Part A: Liraglutide | Part B: Liraglutide | Part A: Placebo | Part B: Placebo |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 10/20 | 7/17 | 2/12 | 0/7 |
| Abdominal painGastrointestinal disorders | 6/20 | 3/17 | 3/12 | 0/7 |
| InfluenzaInfections and infestations | 2/20 | 2/17 | 1/12 | 2/7 |
| HeadacheNervous system disorders | 2/20 | 2/17 | 3/12 | 0/7 |
| Abdominal pain upperGastrointestinal disorders | 1/20 | 3/17 | 0/12 | 0/7 |
| VomitingGastrointestinal disorders | 2/20 | 3/17 | 0/12 | 0/7 |
| MalaiseGeneral disorders | 1/20 | 0/17 | 2/12 | 0/7 |
| ConstipationGastrointestinal disorders | 3/20 | 0/17 | 0/12 | 0/7 |
| NasopharyngitisInfections and infestations | 3/20 | 2/17 | 1/12 | 0/7 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/20 | 2/17 | 0/12 | 1/7 |
Full analysis set (FAS) which included all randomised participants who received at least one dose of trial product and had any post-randomisation data.
| Age, Customized(Participants) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Total |
|---|---|---|---|---|---|
| 6 - <12 years | 0 | 0 | 17 | 7 | 24 |
| 12 - <18 years | 19 | 12 | 0 | 0 | 31 |
| Sex: Female, Male(Participants) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Total |
|---|---|---|---|---|---|
| Female | 10 | 5 | 11 | 2 | 28 |
| Male | 9 | 7 | 6 | 5 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 3 | 1 | 5 |
| Not Hispanic or Latino | 18 | 12 | 11 | 6 | 47 |
| Unknown or Not Reported | 0 | 0 | 3 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Part A: Liraglutide | Part A: Placebo | Part B: Liraglutide | Part B: Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 2 | 0 | 1 | 0 | 3 |
| White | 11 | 6 | 10 | 7 | 34 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 6 | 5 | 0 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Nov 2015 to primary completion in Nov 2020, 59 months.
Results were first posted in Feb 2022, 1 year 2 months after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 59 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide